Reza Yaesoubi, PhD
Cards
Titles
Affiliated Faculty, Yale Institute for Global Health; Affiliated Faculty, Yale Institute for Foundations of Data Science
Contact Info
About
Titles
Associate Professor of Public Health (Health Policy)
Affiliated Faculty, Yale Institute for Global Health; Affiliated Faculty, Yale Institute for Foundations of Data ScienceBiography
Dr. Yaesoubi is a health decision scientist with focus on developing and applying analytical methods to inform decision making in public health and medicine. His expertise is in developing methods to guide decisions when the evidence base and data are shifting too quickly for any static policy or guideline to suffice (e.g., during outbreaks of novel pathogens or spread of antimicrobial-resistant pathogens). Through incorporating computer simulation models, statistical and machine learning methods, and optimization techniques, he has pioneered mechanisms to combine data and evidence from disparate sources to inform cost-effective decisions in real-time. He has applied these methods to optimize public health responses to the spread of drug-resistant tuberculosis, antimicrobial-resistant gonorrhea, COVID-19, influenza, and meningitis. He is also interested in and contributed to the theoretical and methodological issues in medical decision-making and health care resource allocation.
Appointments
Health Policy & Management
Associate Professor on TermPrimary
Other Departments & Organizations
- Health Policy & Management
- Public Health Modeling
- Yaesoubi Lab
- Yale Institute for Global Health
- Yale School of Public Health
Education & Training
- Post-Doctoral Research Fellow
- Brigham and Women’s Hospital (2014)
- Post-Doctoral Research Staff
- IBM Research (2011)
- Post-Doctoral Research Fellow
- Brigham and Women’s Hospital (2010)
- PhD
- North Carolina State University, Industrial and Systems Engineering (2010)
- MSc
- North Carolina State University, Industrial and Systems Engineering (2006)
- BS
- Sharif University of Technology, Industrial Engineering (2004)
Research
Overview
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Ted Cohen, DPH, MD, MPH
A. David Paltiel, MBA, PhD
Maija Cheung, MD, FACS
Mona Sharifi, MD, MPH
Deus Thindwa, PhD
Gregg Gonsalves, PhD
Cost-Benefit Analysis
Epidemics
Tuberculosis
Gonorrhea
Influenza, Human
Computer Simulation
Publications
2024
Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis.
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchAltmetricConceptsDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyHow many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?
Yaesoubi R. How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses? Value In Health 2024 PMID: 38977192, DOI: 10.1016/j.jval.2024.06.016.Peer-Reviewed Original ResearchConceptsProbabilistic sensitivity analysesIncremental cost-effectiveness ratioProbabilistic cost-effectiveness analysisCost-effectiveness analysisEstimate incremental cost-effectiveness ratiosIncremental cost-effectiveness ratio estimatesCost-effectiveness ratioDecision optionsStochastic modelPresence of parameter uncertaintiesCostParameter uncertaintiesUncertaintyLevel of accuracyInequalitySensitivity analysisEstimationMonteModelMonte Carlo samplingParameter samplesChebyshev inequalityImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchAltmetricConceptsQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2023
The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States
Yaesoubi R, Xi Q, Hsu K, Gift T, St. Cyr S, Rönn M, Salomon J, Grad Y. The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States. American Journal Of Epidemiology 2023, 193: 17-25. PMID: 37625444, PMCID: PMC10773484, DOI: 10.1093/aje/kwad175.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRapid drug susceptibility testDrug susceptibility testGonorrhea casesSusceptibility testsFirst-line treatmentBurden of gonorrheaGonococcal infectionGonorrhoea transmissionAntibiotic treatmentPatient outcomesIndividualized treatmentLife spanDrug susceptibilityCare testRapid pointEffective life spanAntibiotic resistanceAntibioticsTest specificityGonorrheaMenCiprofloxacinTreatmentCorrect ascertainmentLong-term impactResistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study
Reichert E, Yaesoubi R, Rönn M, Gift T, Salomon J, Grad Y. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study. The Lancet Microbe 2023, 4: e781-e789. PMID: 37619582, PMCID: PMC10865326, DOI: 10.1016/s2666-5247(23)00145-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPrevalence of resistancePrimary outcomeGonococcal infectionGonorrhea treatmentCombination therapyAntibiotic resistanceResistance emergenceNew antibioticsNew drugsUrgent public health concernCombination therapy strategiesSexual activity groupsPopulation-level prevalencePublic health concernSecondary outcomesAnnual incidenceGonorrhoea transmissionCurrent therapiesMSM populationUS CentersMathematical modelling studyCurrent drugsUS populationNeisseria gonorrhoeaeInfectious diseasesCost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity
Pryor S, Savoye M, Nowicka P, Price G, Sharifi M, Yaesoubi R. Cost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity. Value In Health 2023, 26: 1183-1191. PMID: 36967028, PMCID: PMC10518029, DOI: 10.1016/j.jval.2023.03.006.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBody mass indexClinical controlMedical Expenditure Panel Survey dataClinical weight managementHealth system perspectivePrevention growth chartsParticipants' body mass indexFamily-based interventionsMass indexChildhood obesityBMI trajectoriesWeight managementHealthcare costsPrimary analysisGrowth chartsObesityTrial dataDisease controlMedical expendituresBright bodiesHealthcare expendituresIncremental costIntervention costsBody interventionsChildrenCost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitionsThe Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018
Li Y, You S, Lee K, Yaesoubi R, Hsu K, Gift T, Chesson H, Berruti A, Salomon J, Rönn M. The Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018. The Journal Of Infectious Diseases 2023, 227: 1007-1018. PMID: 36806950, PMCID: PMC10112678, DOI: 10.1093/infdis/jiad047.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLifetime QALYsSubstantial health lossesDuration of infectionCost-effectiveness analysisGenital chlamydiaInfection interventionTotal QALYsIncident infectionsChronic sequelaeInfection helpGonorrheaAge groupsChlamydiaInfectionMultivariate sensitivity analysisHealth lossTrichomoniasisQALYWomenSequelaeUnited StatesPrevention policiesQALYsPopulation levelLifetime qualityLifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study
You S, Yaesoubi R, Lee K, Li Y, Eppink S, Hsu K, Chesson H, Gift T, Berruti A, Salomon J, Rönn M. Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study. The Lancet Regional Health - Americas 2023, 19: 100427. PMID: 36950038, PMCID: PMC10025423, DOI: 10.1016/j.lana.2023.100427.Peer-Reviewed Original ResearchCitationsAltmetricConceptsQuality-adjusted life yearsGenital HSV-1Lifetime quality-adjusted life yearsGenital herpesHSV-2HSV-1Neonatal herpesLife yearsNatural historyLifetime numberNeonatal herpes infectionSubstantial health lossesHealth lossHSV-2 infectionLong-term health impactsHerpes simplex virus type 1Adverse health outcomesDays of lifeSimplex virus type 1Virus type 1Health impactsMollaret's meningitisSacral radiculitisSymptomatic recurrenceUrinary retentionGenerating simple classification rules to predict local surges in COVID-19 hospitalizations
Yaesoubi R, You S, Xi Q, Menzies N, Tuite A, Grad Y, Salomon J. Generating simple classification rules to predict local surges in COVID-19 hospitalizations. Health Care Management Science 2023, 26: 301-312. PMID: 36692583, PMCID: PMC9872755, DOI: 10.1007/s10729-023-09629-4.Peer-Reviewed Original ResearchCitations
Links & Media
Media
News
- June 30, 2022
Machine Learning Model Helps Identify Resistance to Key Antibiotics for Treating Tuberculosis
- May 02, 2022
Fetal Alcohol Exposure Data Underscore Need For Public Health Interventions
- July 01, 2021Source: Health Day
Alcohol Still a Threat in Too Many American Pregnancies: Study
- June 28, 2021Source: Yale News
Fetal Alcohol Exposure Data Underscore Need for Public Health Interventions
Get In Touch
Contacts
Administrative Support